The estimated Net Worth of Iv Lpfrazier Healthcare Iv ... is at least $5.24 Million dollars as of 4 February 2008. Iv Iv owns over 69,359 units of Amicus Therapeutics Inc stock worth over $5,240,843 and over the last 17 years Iv sold FOLD stock worth over $0.
Sign up
Iv Iv FOLD stock SEC Form 4 insiders trading
Iv has made over 12 trades of the Amicus Therapeutics Inc stock since 2007, according to the Form 4 filled with the SEC. Most recently Iv bought 69,359 units of FOLD stock worth $717,172 on 4 February 2008.
The largest trade Iv's ever made was buying 69,359 units of Amicus Therapeutics Inc stock on 4 February 2008 worth over $717,172. On average, Iv trades about 25,641 units every 16 days since 2007. As of 4 February 2008 Iv still owns at least 465,026 units of Amicus Therapeutics Inc stock.
You can see the complete history of Iv Iv stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Insiders trading at Amicus Therapeutics Inc
Over the last 17 years, insiders at Amicus Therapeutics Inc have traded over $306,740,337 worth of Amicus Therapeutics Inc stock and bought 23,821,602 units worth $176,323,212 . The most active insiders traders include Advisors Llcperceptive Life..., Peter J Barris und Plc Gsk. On average, Amicus Therapeutics Inc executives and independent directors trade stock every 10 days with the average trade being worth of $830,419. The most recent stock trade was executed by Bradley L Campbell on 3 September 2024, trading 7,500 units of FOLD stock currently worth $64,575.
What does Amicus Therapeutics Inc do?
amicus therapeutics is a global, patient-centric biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare metabolic diseases. we have a unique set of platform technologies and medicines in development for patients living with the lysosomal storage disorders fabry disease and pompe disease and we are committed to advancing and expanding a robust pipeline of cutting-edge, first- or best-in-class medicines for these and other rare diseases. the needs of patients in the rare disease community are at the center of our inventive science, our commercial organization, and our clinical programs. our goal throughout all levels of the organization is to make a meaningful difference in the lives of these patients and their caregivers. several opportunities are available to join our team as we build a leading global biotechnology company focused on rare metabolic diseases. our amicus footprint spans 27 countries including our g
What does Amicus Therapeutics Inc's logo look like?
Complete history of Iv Iv stock trades at Amicus Therapeutics Inc
Amicus Therapeutics Inc executives and stock owners
Amicus Therapeutics Inc executives and other stock owners filed with the SEC include:
-
John Crowley,
Chairman of the Board and Chief Executive Officer -
Bradley Campbell,
President, Chief Operating Officer, Director -
Ellen Rosenberg,
General Counsel, Corporate Secretary, Chief Legal Officer -
Hung Do,
Chief Scientific Officer -
Daphne Quimi,
Chief Financial Officer -
Jay Barth,
Chief Medical Officer -
John F. Crowley,
Chairman & CEO -
Bradley L. Campbell M.B.A.,
Pres, COO & Director -
Daphne E. Quimi CPA,
Chief Financial Officer -
Ellen S. Rosenberg,
Chief Legal Officer & Corp. Sec. -
Burke Whitman,
Independent Director -
Michael Raab,
Lead Independent Director -
Glenn Sblendorio,
Independent Director -
Margaret McGlynn,
Independent Director -
Lynn Bleil,
Independent Director -
Craig Wheeler,
Independent Director -
Robert Essner,
Independent Director -
David Clark,
Chief People Officer -
Samantha Prout,
Principal Accounting Officer, Vice President - Finance, Controller -
Jayne C. Gershkowitz,
Chief Patient Advocate -
David M. Clark,
Chief People Officer -
Diana Moore,
Head of Global Corp. Communications -
Patrik S. Florencio,
Sr. VP, Global Chief Compliance & Risk Officer -
Andrew Faughnan,
Sr. Director of Investor Relations -
William D Iii Baird,
Chief Financial Officer -
Kurt J. Andrews,
SVP, Human Resources -
Ted W Love,
Director -
Advisors Llcedelman Josephp...,
-
Donald J Jr Hayden,
Director -
Advisors Llcperceptive Life...,
-
Michael Aaron Kelly,
-
Group, Llc Green Jeremy Red...,
-
Sol J Barer,
Director -
Jayne Gershkowitz,
VP, Patient Advocacy -
Julie Yu,
Vice President Clinical Ops -
Kenneth Peist,
VP, Intellectual Property -
Sinai School Of Medicine Of...,
10% owner -
David Palling,
Senior VP, Drug Development -
Orlov S Nicole Schaeffer,
VP,HR & Leadership Development -
Iv Lpfrazier Healthcare Iv ...,
-
Pol F Boudes,
Chief Medical Officer -
Bio Ventures Lp Quaker,
10% owner -
Mark W Perry,
10% owner -
David J Lockhart,
Chief Scientific Officer -
Alexander E Barkas,
Director -
Enrique Dilone,
VP, Technical Operations -
Robert E Winkler,
VP, Clin Research & Operations -
Peter J Barris,
10% owner -
M James Barrett,
Director -
Mc Adam M John,
Corporate Controller -
Iv Lp Frazier Healthcare V,...,
-
Venture Partners Ii Lpprosp...,
-
Plc Gsk,
10% owner -
Matthew R Patterson,
Chief Operating Officer -
Medical Partners Ii Side Fu...,
10% owner -
Ken Valenzano,
VP, Pharmacology & Biology -
Stephen M Bloch,
Director -
Andrew Shenker,
VP, Clinical Research -
Allsop David,
SVP International -
James E Dentzer,
Chief Financial Officer. -
Gregory M Weinhoff,
Director -
Geoffrey Gilmore,
Senior VP, General Counsel -
Iv Lpfrazier Healthcare Iv ...,
-
Peter M Macaluso,
VP & Corporate Counsel -
Iv Lpfrazier Healthcare Iv ...,
-
State Life Sciences Venture...,
10% owner -
Mark Baldry,
VP Global Marketing -
James N Topper,
Director -
Enterprise Associates 11 Lp...,
-
C Richard Kramlich,
10% owner -
Charles W Iii Newhall,
10% owner -
P Sherrill Neff,
Director -
Gregory P Licholai,
VP, Medical Affairs -
Iv Lp Frazier Healthcare V,...,
-
John Kirk,
VP, Regulatory Affairs -
Dipal Doshi,
SVP Business Planning & Dev -
Joan Winterbottom,
SVP, Human Resources -
Medical Partners Ii, L.P. Chl,
10% owner -
Enterprise Associates 11 Lp...,
-
Eiry Roberts,
-
Jeff Castelli,
Chief Development Officer -
Simon N.R. Harford,
Chief Financial Officer